We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management...
For manufacturers and distributors of intermediate and final feedingstuffs containing a medicinal premix or specified feed additives in Great Britain and Northern Ireland.
Summary of the latest safety advice for medicines and medical device users
Details of the suspension of the marketing authorisation of Levothyroxine 100 microgram tablets, including MHRA investigations.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
Guidance for the pharmaceutical industry on Marketing Authorisations for veterinary medicines in the UK.
List of words and phrases that will cause a veterinary product to be medicinal by presentation either through use or contextual use.
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).